Formulations for epidural repair
AssigneeClaridei Laboratories, Inc.
InventorCheryl Lee Eberting
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to dermatological formulations and their use for treating a variety of dermatological diseases and disorders, and for repairing and restoring a disrupted epidermal barrier, inhibiting inflammation, restoring a proper environment for maintaining a balanced symbiotic microbiome, and inhibiting the growth of pathogenic microorganisms in the epidermis—the outer layer of mammalian skin.
Claims21
A composition comprising therapeutically effective amounts of at least one of each of the following:
- 18β-glycyrrhetinic acid;
- a glucocorticoid,
- a ceramide;
- and
- polyhydroxy acid to maintain a pH of 4.6-5.6.
A composition comprising therapeutically effective amounts of the following concentrations of ingredients, in percent weight per weight (w/w):
- a ceramide, 0.0001-10% (w/w);
- at least one of 18β-glycyrrhetinic acid, glycyrrhizic acid, carbenoxolone, chenodeoxycholic acid, or PF-877423, 0.0001-5% (w/w);
- at least one of hydrocortisone, triamcinolone, clobetasol, betamethasone, fluticasone, fluocinonide, 0.001-10.0% (w/w);
- and
- polyhydroxy acid to maintain a pH of 4.6-5.6, X-Y % (w/w).
A composition comprising therapeutically effective amounts of at least one of each of the following:
- a ceramide;
- polyhydroxy acid in an amount to maintain a pH of 4.6-5.6;
- nicotinamide;
- 18β-glycyrrhetinic acid;
- hydrocortisone;
- and
- gluconolactone.
Dependencies are inferred from the claim text.